Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

653 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.
Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, Micallef IN, Porrata LF, Ansell SM, Reeder CB, Roy V, Witzig TE. Johnston PB, et al. Among authors: roy v. Am J Hematol. 2010 May;85(5):320-4. doi: 10.1002/ajh.21664. Am J Hematol. 2010. PMID: 20229590 Free PMC article. Clinical Trial.
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement.
Dispenzieri A, Buadi F, Kumar SK, Reeder CB, Sher T, Lacy MQ, Kyle RA, Mikhael JR, Roy V, Leung N, Grogan M, Kapoor P, Lust JA, Dingli D, Go RS, Hwa YL, Hayman SR, Fonseca R, Ailawadhi S, Bergsagel PL, Chanan-Khan A, Rajkumar SV, Russell SJ, Stewart K, Zeldenrust SR, Gertz MA. Dispenzieri A, et al. Among authors: roy v. Mayo Clin Proc. 2015 Aug;90(8):1054-81. doi: 10.1016/j.mayocp.2015.06.009. Mayo Clin Proc. 2015. PMID: 26250727 Review.
Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.
Kumar SK, Krishnan A, LaPlant B, Laumann K, Roy V, Zimmerman T, Gertz MA, Buadi FK, Stockerl Goldstein K, Birgin A, Fiala M, Duarte L, Maharaj M, Levy J, Vij R. Kumar SK, et al. Among authors: roy v. Am J Hematol. 2015 Dec;90(12):1106-10. doi: 10.1002/ajh.24181. Epub 2015 Oct 6. Am J Hematol. 2015. PMID: 26331432 Free article. Clinical Trial.
Nuances in the Management of Older People With Multiple Myeloma.
Pawlyn C, Gay F, Larocca A, Roy V, Ailawadhi S. Pawlyn C, et al. Among authors: roy v. Curr Hematol Malig Rep. 2016 Jun;11(3):241-51. doi: 10.1007/s11899-016-0323-4. Curr Hematol Malig Rep. 2016. PMID: 27038805 Free article. Review.
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib.
Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, Gertz MA, Bergsagel PL, Dispenzieri A, Thompson MA, Crawley J, Kapoor P, Mikhael J, Stewart K, Hayman SR, Hwa YL, Gonsalves W, Witzig TE, Ailawadhi S, Dingli D, Go RS, Lin Y, Rivera CE, Rajkumar SV, Lacy MQ. Kumar SK, et al. Among authors: roy v. Blood. 2016 Nov 17;128(20):2415-2422. doi: 10.1182/blood-2016-05-717769. Epub 2016 Oct 4. Blood. 2016. PMID: 27702799 Free PMC article. Clinical Trial.
Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.
Paulus A, Akhtar S, Caulfield TR, Samuel K, Yousaf H, Bashir Y, Paulus SM, Tran D, Hudec R, Cogen D, Jiang J, Edenfield B, Novak A, Ansell SM, Witzig T, Martin P, Coleman M, Roy V, Ailawadhi S, Chitta K, Linder S, Chanan-Khan A. Paulus A, et al. Among authors: roy v. Blood Cancer J. 2016 Nov 4;6(11):e492. doi: 10.1038/bcj.2016.93. Blood Cancer J. 2016. PMID: 27813535 Free PMC article.
653 results